Theracryf Plc
Research Theracryf Plc (TCF) on Bullrun: market cap GBX 408.30M. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerTCF
- ExchangeLSE
- CountryUnited Kingdom
- SectorHealthcare
- IndustryBiotechnology
- CurrencyGBX
- Market capGBX 408.30M
- Financial periodFY2025
- RevenueGBP 0
- Revenue growth-100.0%
- Net income-GBP 1.94M
- Free cash flow-GBP 2.37M
Valuation Snapshot
latest market cap is GBX 408.30M.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | GBP 0 | -GBP 1.94M | -GBP 2.37M | n/a | 0 | GBP 2.11M | n/a | GBP 5.97M |
| FY2024 | GBP 396.00K | -GBP 3.14M | -GBP 3.00M | n/a | -0.01 | GBP 2.00M | n/a | GBP 2.34M |
| FY2023 | GBP 442.00K | -GBP 4.04M | -GBP 4.13M | n/a | -0.01 | GBP 5.00M | n/a | GBP 5.34M |
| FY2022 | GBP 0 | -GBP 2.73M | -GBP 2.59M | n/a | -0.01 | GBP 4.51M | n/a | GBP 9.23M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-08-29 | GBX 408.30M | n/a | n/a | 0 |
Dividend history
Latest trailing dividend snapshot: annual dividend/share 0 GBX.
About Theracryf Plc
Theracryf Plc, a clinical stage therapeutics company, engages in the development of therapeutics for oncology and behavioural brain disorders. The company develops orexin-1 antagonist for the treatment of binge eating disorder and anxiety; and atypical dopamine transporter inhibitor (DAT) to treat fatigue and narcolepsy. It also develops SFX-01 for the treatment of brain cancer glioblastoma and neurodevelopmental disorders.
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Theracryf Plc's market cap?
Theracryf Plc's market capitalization is GBX 408.30M.
What does Theracryf Plc do?
Theracryf Plc, a clinical stage therapeutics company, engages in the development of therapeutics for oncology and behavioural brain disorders. The company develops orexin-1 antagonist for the treatment of binge eating disorder and anxiety; and atypical dopamine transporter inhibitor (DAT) to treat fatigue and narcolepsy. It also develops SFX-01 for the treatment of brain cancer glioblastoma and neurodevelopmental disorders. The company was formerly known as Evgen Pharma plc and changed its name to Theracryf Plc in April 2024.